Overview Dividends

(UNH) UnitedHealth - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US91324P1021

Health Insurance, Care Management, Pharmacy Services, Health Analytics

Managed Health Care
Market Cap in USD: 297,450m
IPO / Inception: 1984-10-26
Return 12m vs S&P 500: -41.7%

EPS (Earnings per Share)

EPS (Earnings per Share) of UNH over the last years for every Quarter: "2020-12": 2.52, "2021-03": 5.31, "2021-06": 4.7, "2021-09": 4.52, "2021-12": 4.48, "2022-03": 5.49, "2022-06": 5.57, "2022-09": 5.79, "2022-12": 5.34, "2023-03": 6.26, "2023-06": 6.14, "2023-09": 6.56, "2023-12": 6.16, "2024-03": 6.91, "2024-06": 6.8, "2024-09": 6.51, "2024-12": 6.81, "2025-03": 6.85, "2025-06": 4.08, "2025-09": 2.92,
EPS CAGR: -10.79%
EPS Trend: -19.6%
Last SUE: 0.51
Qual. Beats: 0

Revenue

Revenue of UNH over the last years for every Quarter: 2020-12: 65467, 2021-03: 70196, 2021-06: 71321, 2021-09: 72337, 2021-12: 73743, 2022-03: 80149, 2022-06: 80332, 2022-09: 80894, 2022-12: 82787, 2023-03: 91931, 2023-06: 92903, 2023-09: 92361, 2023-12: 94427, 2024-03: 99796, 2024-06: 98855, 2024-09: 100820, 2024-12: 100807, 2025-03: 109575, 2025-06: 111616, 2025-09: 113161,
Rev. CAGR: 12.10%
Rev. Trend: 97.9%
Last SUE: 0.08
Qual. Beats: 0

Dividends

Dividend Yield 2.67%
Yield on Cost 5y 2.82%
Yield CAGR 5y 14.08%
Payout Consistency 96.0%
Payout Ratio 42.3%
Risk via 5d forecast
Volatility 35.0%
Value at Risk 5%th 43.2%
Relative Tail Risk -25.06%
Reward TTM
Sharpe Ratio -0.68
Alpha -37.87
CAGR/Max DD -0.22
Character TTM
Hurst Exponent 0.552
Beta 0.282
Beta Downside 0.111
Drawdowns 3y
Max DD 61.39%
Mean DD 16.84%
Median DD 9.42%

Description: UNH UnitedHealth December 01, 2025

UnitedHealth Group (UNH) is a diversified health-care conglomerate operating through four distinct segments: UnitedHealthcare (commercial, Medicare, Medicaid and individual plans), Optum Health (care delivery and management services), Optum Insight (data-analytics, software and consulting) and Optum Rx (pharmacy-benefit and specialty-pharmacy services). The firm serves a broad customer base-from large employers and government programs to individual consumers-both in the United States and internationally, positioning itself as a one-stop provider of health-benefit, data, and pharmacy solutions.

Key recent metrics underscore UNH’s scale and growth trajectory: FY 2023 revenue reached $44.9 billion with an operating margin of roughly 13 %, and the company reported about 52 million members across its UnitedHealthcare and Optum lines. Medicare Advantage enrollment grew ~5 % YoY in Q4 2023, reflecting demographic aging and the shift toward value-based care. Looking ahead, UNH has guided FY 2024 revenue growth of ~5 % and an EPS target near $15.50, while maintaining strong cash conversion (~$5 billion) to fund acquisitions and technology investments.

For a deeper quantitative dive, you might explore ValueRay’s UNH valuation models.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (17.59b TTM) > 0 and > 6% of Revenue (6% = 26.11b TTM)
FCFTA 0.06 (>2.0%) and ΔFCFTA 1.13pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue -4.70% (prev -2.36%; Δ -2.34pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.07 (>3.0%) and CFO 20.96b > Net Income 17.59b (YES >=105%, WARN >=100%)
Net Debt (52.93b) to EBITDA (30.52b) ratio: 1.73 <= 3.0 (WARN <= 3.5)
Current Ratio 0.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (912.0m) change vs 12m ago -1.94% (target <= -2.0% for YES)
Gross Margin 19.70% (prev 22.87%; Δ -3.17pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 141.6% (prev 131.6%; Δ 10.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 6.51 (EBITDA TTM 30.52b / Interest Expense TTM 4.03b) >= 6 (WARN >= 3)

Altman Z'' 1.64

(A) -0.06 = (Total Current Assets 95.07b - Total Current Liabilities 115.53b) / Total Assets 315.27b
(B) 0.31 = Retained Earnings (Balance) 97.59b / Total Assets 315.27b
(C) 0.09 = EBIT TTM 26.24b / Avg Total Assets 307.29b
(D) 0.46 = Book Value of Equity 95.39b / Total Liabilities 209.46b
Total Rating: 1.64 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 73.21

1. Piotroski 6.50pt
2. FCF Yield 4.96%
3. FCF Margin 3.99%
4. Debt/Equity 0.84
5. Debt/Ebitda 1.73
6. ROIC - WACC (= 6.11)%
7. RoE 18.60%
8. Rev. Trend 97.94%
9. EPS Trend -19.56%

What is the price of UNH shares?

As of December 21, 2025, the stock is trading at USD 327.42 with a total of 10,550,011 shares traded.
Over the past week, the price has changed by -4.22%, over one month by +6.64%, over three months by -2.10% and over the past year by -31.43%.

Is UNH a buy, sell or hold?

UnitedHealth has received a consensus analysts rating of 4.15. Therefore, it is recommended to buy UNH.
  • Strong Buy: 14
  • Buy: 6
  • Hold: 5
  • Sell: 1
  • Strong Sell: 1

What are the forecasts/targets for the UNH price?

Issuer Target Up/Down from current
Wallstreet Target Price 388.5 18.7%
Analysts Target Price 388.5 18.7%
ValueRay Target Price 318.4 -2.8%

UNH Fundamental Data Overview December 12, 2025

Market Cap USD = 297.45b (297.45b USD * 1.0 USD.USD)
P/E Trailing = 17.1204
P/E Forward = 18.5529
P/S = 0.6835
P/B = 3.1053
P/EG = 1.2493
Beta = 0.432
Revenue TTM = 435.16b USD
EBIT TTM = 26.24b USD
EBITDA TTM = 30.52b USD
Long Term Debt = 72.40b USD (from longTermDebt, last quarter)
Short Term Debt = 7.74b USD (from shortTermDebt, last quarter)
Debt = 80.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 52.93b USD (from netDebt column, last quarter)
Enterprise Value = 350.38b USD (297.45b + Debt 80.14b - CCE 27.21b)
Interest Coverage Ratio = 6.51 (Ebit TTM 26.24b / Interest Expense TTM 4.03b)
FCF Yield = 4.96% (FCF TTM 17.37b / Enterprise Value 350.38b)
FCF Margin = 3.99% (FCF TTM 17.37b / Revenue TTM 435.16b)
Net Margin = 4.04% (Net Income TTM 17.59b / Revenue TTM 435.16b)
Gross Margin = 19.70% ((Revenue TTM 435.16b - Cost of Revenue TTM 349.43b) / Revenue TTM)
Gross Margin QoQ = 18.24% (prev 17.93%)
Tobins Q-Ratio = 1.11 (Enterprise Value 350.38b / Total Assets 315.27b)
Interest Expense / Debt = 1.25% (Interest Expense 1.00b / Debt 80.14b)
Taxrate = 21.24% (686.0m / 3.23b)
NOPAT = 20.66b (EBIT 26.24b * (1 - 21.24%))
Current Ratio = 0.82 (Total Current Assets 95.07b / Total Current Liabilities 115.53b)
Debt / Equity = 0.84 (Debt 80.14b / totalStockholderEquity, last quarter 95.79b)
Debt / EBITDA = 1.73 (Net Debt 52.93b / EBITDA 30.52b)
Debt / FCF = 3.05 (Net Debt 52.93b / FCF TTM 17.37b)
Total Stockholder Equity = 94.55b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.58% (Net Income 17.59b / Total Assets 315.27b)
RoE = 18.60% (Net Income TTM 17.59b / Total Stockholder Equity 94.55b)
RoCE = 15.72% (EBIT 26.24b / Capital Employed (Equity 94.55b + L.T.Debt 72.40b))
RoIC = 11.88% (NOPAT 20.66b / Invested Capital 173.93b)
WACC = 5.77% (E(297.45b)/V(377.59b) * Re(7.06%) + D(80.14b)/V(377.59b) * Rd(1.25%) * (1-Tc(0.21)))
Discount Rate = 7.06% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.24%
[DCF Debug] Terminal Value 79.83% ; FCFE base≈15.66b ; Y1≈17.52b ; Y5≈23.25b
Fair Price DCF = 445.2 (DCF Value 403.27b / Shares Outstanding 905.8m; 5y FCF grow 13.70% → 3.0% )
EPS Correlation: -19.56 | EPS CAGR: -10.79% | SUE: 0.51 | # QB: 0
Revenue Correlation: 97.94 | Revenue CAGR: 12.10% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=6.58 | Chg30d=-0.049 | Revisions Net=+0 | Analysts=18
EPS next Year (2026-12-31): EPS=17.71 | Chg30d=+0.015 | Revisions Net=+4 | Growth EPS=+8.6% | Growth Revenue=+2.2%

Additional Sources for UNH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle